Crucell Announces PER.C6(R) and AdVac(R) Technology License Agreement with Wyeth Pharmaceuticals

Leiden, The Netherlands, July 30 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.

Crucell's AdVac® technology is a recombinant vector technology used to develop novel adenoviral-based products.

PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1,000 people. For more information, please visit www.crucell.com .

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 13 2007 and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                      For Crucell in the US:
Leonard Kruimer                   Redington, Inc.
Chief Financial Officer           Thomas Redington
Tel.  31-(0)71- 519 9100          Tel.  1 212-926-1733
 Leonard.Kruimer@crucell.com         tredington@redingtoninc.com 

Barbara Mulder
Director Corporate Communications
Tel: 31-(0) 71 519 7346
 barbara.mulder@crucell.com